Focus Partners Advisor Solutions’s ImmunityBio IBRX Stock Holding History

Focus Partners Advisor Solutions’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,161	Closed	-$25K	–	1182
2025 Q3	$25K	Sell	10,161 -2,840	-22%	-$7.31K	﹤0.01%	1126
2025 Q2	$34.3K	Buy	13,001 +2,265	+21%	+$6.09K	﹤0.01%	1083
2025 Q1	$32.3K	Buy	10,736 +315	+3%	+$955	﹤0.01%	958
2024 Q4	$26.7K	Buy	10,421 +393	+4%	+$1.64K	﹤0.01%	767
2024 Q3	$37.3K	Sell	10,028 -285	-3%	-$1.32K	﹤0.01%	747
2024 Q2	$65.2K	Buy	+10,313	New	+$68K	﹤0.01%	628

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Focus Partners Advisor Solutions's IBRX Position: Q4 2025 in Review

Focus Partners Advisor Solutions sold out of ImmunityBio (IBRX) in Q4 2025, closing a stake of 10,161 shares — an estimated $25K sold.

Focus Partners Advisor Solutions first reported a position in IBRX in Q2 2024 and held it in 6 quarters. The position peaked at $65.2K in Q2 2024. 276 funds tracked by Wall St. Rank hold IBRX as of Q4 2025.

Focus Partners Advisor Solutions reported no remaining ImmunityBio position as of Q4 2025 after selling out during the quarter.
Focus Partners Advisor Solutions sold 10,161 ImmunityBio shares in Q4 2025, an estimated $25K.
Focus Partners Advisor Solutions first reported a position in ImmunityBio in Q2 2024 and held it in 6 quarters.
Focus Partners Advisor Solutions's ImmunityBio position peaked at $65.2K in Q2 2024.
276 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2025.

Based on Focus Partners Advisor Solutions's 13F filing for Q4 2025, filed 11 Feb 2026.